Status:
UNKNOWN
Effects of Recombinant Human Thrombopoietin on Platelet Levels in ICU Patients
Lead Sponsor:
Nanfang Hospital, Southern Medical University
Collaborating Sponsors:
The Third Affiliated Hospital of Southern Medical University
The Second People's Hospital of GuangDong Province
Conditions:
Pneumonia
Thrombocytopenia
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The incidence of thrombocytopenia in ICU patients with severe illness ranged from 8.3% to 67.6%, and ranged from 14% to 44% during ICU treatment.Severe patients with thrombocytopenia also have signifi...
Eligibility Criteria
Inclusion
- Clinical diagnosis of pneumonia (community acquired pneumonia, hospital acquired pneumonia or ventilator associated pneumonia);
- Voluntarily signed informed consent;
- ≥18 years old;
- Platelet count ≤75×109/L
Exclusion
- A history of hematopoietic stem cell transplantation or solid organ transplantation such as liver, kidney or lung;
- Hematological malignancy;
- Immune thrombocytopenia, such as SLE, ITP, TTP, etc.
- The length of stay in ICU is less than 24h;
- Pregnant or lactation patients;
Key Trial Info
Start Date :
February 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2023
Estimated Enrollment :
178 Patients enrolled
Trial Details
Trial ID
NCT05217719
Start Date
February 1 2022
End Date
October 1 2023
Last Update
February 1 2022
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.